title: Downregulation of CXCR5 in CD27- B cells of HIV-1 infected patients.
abstract: The CD27(-) (naive) B cells of HIV-1 infected patients have been shown to be increased in frequency and to be activated, as indicated by high CD38 expression on the cell surface. CXCR5, a B cell chemokine receptor, is expressed on circulating CD27(-) (naive) B cells and plays a pivotal role in peripheral B cell development. To investigate the effect of HIV-1 infection on the expression of this chemokine receptor on naive B cells, the expression level of CXCR5 on CD27(-) B cells was examined in 19 drug-naive HIV-1 infected patients, 27 HAART-treated patients, and 20 controls. CXCR5 expression on CD27(-) B cells was significantly lower in drug-naive patients than in HAART-treated patients and controls (P < 0.01). CD27(-) B cells with high CD38 expression exhibited low CXCR5 expression. The CXCR5 expression level on CD27(-) B cells recovered to within the normal range after effective antiretroviral therapy. These findings suggested that HIV-1 infection induces a remarkable phenotypic alteration of naive B cells and that the activated naive B cells found in HIV-1 infection downregulate CXCR5 on their surface. Impaired homing of naive B cells may contribute to HIV-1 induced immunological deficiencies.
authors.affiliation: Department of General Medicine, Kyushu University Hospital, Higashiku, Fukuoka, Japan. chong@genmedpr.med.kyushu-u.ac.jp
authors.forename: Yong
authors.initials: Y
authors.lastname: Chong
authors.forename: Shigeki
authors.initials: S
authors.lastname: Nabeshima
authors.forename: Norihiro
authors.initials: N
authors.lastname: Furusyo
authors.forename: Masayuki
authors.initials: M
authors.lastname: Murata
authors.forename: Kouzaburo
authors.initials: K
authors.lastname: Yamaji
authors.forename: Jun
authors.initials: J
authors.lastname: Hayashi
mesh_terms: D036541:ADP-ribosyl Cyclase / Q000032:analysis; D051997:ADP-ribosyl Cyclase 1; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D015703:Antigens, CD / Q000032:analysis; D023241:Antiretroviral Therapy, Highly Active; D016175:B-Lymphocyte Subsets / Q000276:immunology*; D015536:Down-Regulation; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D018655:Lymphocyte Count; D008562:Membrane Glycoproteins; D054380:Receptors, CXCR5; D019707:Receptors, Chemokine; D018121:Receptors, Cytokine / Q000378:metabolism*; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000032:analysis
chemical_list: D019380:Anti-HIV Agents; D015703:Antigens, CD; C095085:CXCR5 protein, human; D008562:Membrane Glycoproteins; D054380:Receptors, CXCR5; D019707:Receptors, Chemokine; D018121:Receptors, Cytokine; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1